Pachymic acid
(Synonyms: 茯苓酸; 3-O-Acetyltumulosic acid) 目录号 : GN10752
A triterpenoid with diverse biological activities
Cas No.:29070-92-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Pachymic acid is a lanostrane-type triterpenoid from P. cocos. Pachymic acid inhibits Akt and ERK signaling pathways.
Pachymic acid (PA) is able to inhibit gallbladder cancer tumorigenesis involving affection of Akt and ERK signaling pathways. Pachymic acid (PA) treatment significantly inhibits Rho A, Akt and ERK pathway in gallbladder carcinoma cells. Pachymic acid (PA) treatment can dose-dependently downregulate PCNA, ICAM-1, RhoA, p-Akt and pERK. Cell growth is inhibited by 10 µg/mL Pachymic acid (PA) 12 h after treatment, and a concentration of 30 µg/mL further reduced cell growth. The growth of cells is suppressed in a time- and dose-dependent manner. After 48 h treatment, about 25%, 40% and 70% of the cell growth are inhibited by Pachymic acid (PA) at concentration of 10 µg/mL, 20 µg/mL and 30 µg/mL, respectively. Pachymic acid (PA) also inhibits the growth of gallbladder carcinoma cells in a time-dependent and dose-dependent manner[1].
To evaluate the anti-tumor activity of Pachymic acid (PA) in vivo, human lung cancer NCI-H23 tumor xenograft models are used. Pachymic acid (PA) significantly suppresses tumor growth at doses of 30 and 60 mg/kg for 21 days compared with the control group[2].
References:
[1]. Chen Y, et al. Pachymic acid inhibits tumorigenesis in gallbladder carcinoma cells. Int J Clin Exp Med. 2015 Oct 15;8(10):17781-8.
[2]. Ma J, et al. Pachymic acid induces apoptosis via activating ROS-dependent JNK and ER stress pathways in lung cancer cells. Cancer Cell Int. 2015 Aug 5;15:78.
|
Cell experiment: |
The antiproliferative effect of Pachymic acid (PA) on GBC-SD cells is evaluated using a cell counting kit-8 (CCK-8). Briefly, after indicated treatment, 10 µL of CCK-8 solution is added into each well, and following one hincubation, absorbance is measured at 450 nm using a microplate reader[1]. |
|
Animal experiment: |
Mice[2] Female athymic nude mice of 4-5 weeks of age are used. Exponentially growing NCI-H23 cells (5×106 in 100 µL PBS) are injected subcutaneously in the right flank of each mouse. Tumor xenografts are allowed to grow to an average size of 100-200 mm3 and are randomly assigned to four different treatment groups (six mice per group): (a) vehicle control (0.1% DMSO in physiological saline); (b) Pachymic acid (PA) 10 mg/kg; (c) PA 30 mg/kg; (Dd) PA 60 mg/kg. The mice are administered PA via intraperitoneal (ip) injections for 3 weeks (5 days/week). Tumor size is measured on two axes with the aid of Vernier calipers and tumor volume (mm3) is calculated. |
|
References: [1]. Chen Y, et al. Pachymic acid inhibits tumorigenesis in gallbladder carcinoma cells. Int J Clin Exp Med. 2015 Oct 15;8(10):17781-8. |
|
| Cas No. | 29070-92-6 | SDF | |
| 别名 | 茯苓酸; 3-O-Acetyltumulosic acid | ||
| 化学名 | (2R)-2-[(3S,5R,10S,13R,14R,16R,17R)-3-acetyloxy-16-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid | ||
| Canonical SMILES | CC(C)C(=C)CCC(C1C(CC2(C1(CCC3=C2CCC4C3(CCC(C4(C)C)OC(=O)C)C)C)C)O)C(=O)O | ||
| 分子式 | C33H52O5 | 分子量 | 528.76 |
| 溶解度 | DMSO: soluble,Ethanol: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8912 mL | 9.4561 mL | 18.9122 mL |
| 5 mM | 0.3782 mL | 1.8912 mL | 3.7824 mL |
| 10 mM | 0.1891 mL | 0.9456 mL | 1.8912 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet